

Note that this data sheet is not lot-specific. Please consult the vial label and the certificate of analysis for information on specific lots.

**Membrane-type 1 Matrix Metalloproteinase (MT1-MMP, MMP 14)  
prodomain, catalytic domain, and hemopexin domain, His-tagged**

Catalogue Number: 30 100 122

Package Size: 10 µg / 50 µl

Catalogue Number: 30 100 123


Package Size: 200 µg / 1 ml

## 1. Enzyme characteristics

**1.1 Molecular form:** Recombinant soluble pro-MT1-MMP is produced as a periplasmic protein in *E. coli*. The proenzyme consists of amino acid residues Ser<sub>1</sub> . . . Val<sub>501</sub> of human MT1-MMP followed by one Thr-residue and six His-residues. The protein thus contains prodomain, catalytic domain and hemopexin domain of MT1-MMP. The calculated  $M_r$  of recombinant soluble pro-MT1-MMP is 58 200 Da.

**1.2 Purity:** Recombinant pro-MT1-MMP is solubilized in 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM CaCl<sub>2</sub>. The protein appears as a predominant band at 58 kDa in SDS-PAGE (> 80 % of total protein).

**1.3 Stability and storage:** Recombinant pro-MT1-MMP is stable until the expiry date given on the label if stored at -70°C. The proenzyme can be kept at -20°C for several weeks. Repeated freezing and thawing should be avoided.



SDS-PAGE of  
2 µg recombinant  
soluble MT1-MMP

## 2. Applications

Recombinant soluble pro-MT1-MMP is used as antigen for antibody generation and as antigen standard in immunoassays. The proenzyme can be activated with trace amounts of MT1-MMP catalytic domain [1, 2]. Active soluble MT1-MMP is used to study the activation of progelatinase A (matrix metalloproteinase 2) and the degradation of proteins of the extracellular matrix, including fibrillar collagens [1]. Interactions with matrix metalloproteinase inhibitors can also be investigated.

## 3. Introduction to structure and function of membrane-type 1 matrix metalloproteinase

Matrix metalloproteinases (MMPs) are Zn<sup>2+</sup>- and Ca<sup>2+</sup>-dependent endopeptidases which function in the turnover of extracellular matrix components [3]. Presently fifteen secreted MMPs and six membrane-type MMPs are known to be expressed in humans. MT1-MMP consists of 559 amino acid residues with a calculated  $M_r$  of 63 516 Da [4, 5]. The following domains and sequence regions are distinguished in MT1-MMP: Prodomain (Ser<sub>1</sub> - Arg<sub>88</sub>), catalytic domain (Tyr<sub>89</sub> - Gly<sub>261</sub>), junction between catalytic domain and hemopexin domain (Gly<sub>262</sub> - Gly<sub>292</sub>), hemopexin-like domain (Pro<sub>293</sub> - Cys<sub>485</sub>) and C-terminal sequence (Pro<sub>486</sub> - Val<sub>559</sub>) with transmembrane segment. A soluble form of MT1-MMP without transmembrane segment has been found in culture medium of a breast carcinoma cell line [6].

MT1-MMP is expressed in adult lung, placenta, kidney, ovaries, intestine, prostate and spleen [5]. Increased amounts of the enzyme are found in tumor tissues as lung carcinoma, gastric carcinoma [7], colon, breast, head and neck carcinoma [8].

MT1-MMP is activated by removal of its prodomain. The reaction is catalyzed by furin, a subtilysin-type serine protease, which recognizes a motif of four basic amino acid residues located between prodomain and catalytic domain [9].

*Note that this data sheet is not lot-specific. Please consult the vial label and the certificate of analysis for information on specific lots.*

MT1-MMP activates progelatinase A (72-kDa type IV procollagenase) [4, 10, 11] and procollagenase-3 [12] by proteolytic cleavage of their prodomains. The ability of MT1-MMP to activate other matrix metalloproteinases provides potential for enhanced pericellular proteolysis in physiological and pathological processes. In particular, activation of progelatinase A by MT1-MMP is considered to contribute to local degradation of extracellular matrix during cell migration and proliferation. MT1-MMP hydrolyzes also fibrillar collagens I, II and III into characteristic  $\frac{3}{4}$  and  $\frac{1}{4}$  fragments [1,13] and it cleaves a number of other proteins of the extracellular matrix, among them fibronectin, vitronectin, laminin-1 and dermatan sulfate proteoglycan [1,9,13]. The activity of MT1-MMP is poorly inhibited by tissue inhibitor of matrix metalloproteinases-1 (TIMP-1), but efficiently inhibited by TIMP-2 and TIMP-3 [11].

#### 4. References

1. D'Ortho, M.-P., Will, H., Atkinson, S., Butler, G., Messent, A., Gavrilovic, J., Smith, B., Timpl, R., Zardi, L. and Murphy, G. (1997) *Eur. J. Biochem.* **250**, 751-757.
2. Butler, G. S., Butler, M. J., Atkinson, S. J., Will, H., Tamura, T., Schade van Westrum, St., Crabbe, T., Clements, J., d'Ortho, M.-P. and Murphy, G. (1998) *J. Biol. Chem.* **273**, 871-880
3. Nagase, H. and Woessner, J. P. jr. (1999) *J. Biol. Chem.* **274**, 21491-21494.
4. Sato, H., Takino, T., Okada, Y., Cao, J., Shinagawa, A., Yamamoto, E. and Seiki, M. (1994) *Nature* **370**, 61-65.
5. Will, H. and Hinzmann, B. (1995) *Eur. J. Biochem.* **231**, 602-608.
6. Imai, H., Ohuchi, E., Aoki, T., Nomura, H., Fujii, Y., Sato, H., Seiki, M. and Okada, Y. (1996) *Cancer Res.* **56**, 2707-2710.
7. Nomura, H., Sato, H., Seiki, M., Mai, M. and Okada, Y. (1995) *Cancer Res.* **55**, 3263-3266.
8. Okada, A., Bellocq, J.-P., Rouyer, N., Chenard, M.-P., Rio, M.-C., Chambon, P. and Basset, P. (1995) *Proc. Natl. Acad. Sci. USA* **92**, 2730-2734.
9. Pei, D. and Weiss, S.J. (1996) *J. Biol. Chem.* **271**, 9135-9140.
10. Strongin, A.Y., Collier, I., Bannikov, G., Marmer, B. L., Grant, G.A. and Goldberg, G.I. (1995) *J. Biol. Chem.* **270**, 5331-5338.
11. Will, H., Atkinson, S.J., Butler, G., Smith, B. and Murphy, G. (1996) *J. Biol. Chem.* **271**, 17119-17123.
12. Knäuper, V., Will, H., López-Otin, C., Smith, B., Atkinson, S.J., Stanton, H., Hembry, R.M. and Murphy, G. (1996) *J. Biol. Chem.* **271**, 17124-17131.
13. Ohuchi, E., Imai, K., Fujii, Y., Sato, H., Seiki, M. and Okada, Y. (1997) *J. Biol. Chem.* **272**, 2446-2451.